United Therapeutics (UTHR) CFO sells shares after major option exercise

Rhea-AI Filing Summary

United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share and, on the same date, sold 10,000 shares in multiple open-market trades at reported prices such as $518.2830, $529.0430 and $536.2750 per share. Following these transactions, he directly holds 18,876 shares of common stock. The exercise and subsequent sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDGEMOND JAMES

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO AND TREASURER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/23/2026		M(1)		10,000	A	$135.42	28,876	D
Common Stock	03/23/2026		S(1)		200	D	$518.283(2)	28,676	D
Common Stock	03/23/2026		S(1)		640	D	$519.3025(3)	28,036	D
Common Stock	03/23/2026		S(1)		875	D	$520.6164(4)	27,161	D
Common Stock	03/23/2026		S(1)		905	D	$521.4662(5)	26,256	D
Common Stock	03/23/2026		S(1)		200	D	$522.3645(6)	26,056	D
Common Stock	03/23/2026		S(1)		440	D	$524.2001(7)	25,616	D
Common Stock	03/23/2026		S(1)		320	D	$525.37(8)	25,296	D
Common Stock	03/23/2026		S(1)		520	D	$526.5726(9)	24,776	D
Common Stock	03/23/2026		S(1)		80	D	$527.4931(10)	24,696	D
Common Stock	03/23/2026		S(1)		2,620	D	$529.043(11)	22,076	D
Common Stock	03/23/2026		S(1)		577	D	$530.6366(12)	21,499	D
Common Stock	03/23/2026		S(1)		587	D	$531.4904(13)	20,912	D
Common Stock	03/23/2026		S(1)		288	D	$532.5947(14)	20,624	D
Common Stock	03/23/2026		S(1)		642	D	$533.5959(15)	19,982	D
Common Stock	03/23/2026		S(1)		506	D	$534.5972(16)	19,476	D
Common Stock	03/23/2026		S(1)		440	D	$535.3358(17)	19,036	D
Common Stock	03/23/2026		S(1)		160	D	$536.275(18)	18,876	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$135.42	03/23/2026		M			10,000	03/15/2023	03/15/2027	Common Stock	10,000	$0.00	152,500	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.

2. This transaction was executed in multiple trades at prices ranging from $517.82 to $518.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $518.89 to $519.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $519.98 to $520.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $520.99 to $521.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $522.04 to $522.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $523.85 to $524.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $524.98 to $525.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $526.09 to $526.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $527.13 to $528.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. This transaction was executed in multiple trades at prices ranging from $529.02 to $530.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

12. This transaction was executed in multiple trades at prices ranging from $530.05 to $530.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

13. This transaction was executed in multiple trades at prices ranging from $531.08 to $532.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

14. This transaction was executed in multiple trades at prices ranging from $532.09 to $533.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

15. This transaction was executed in multiple trades at prices ranging from $533.09 to $534.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

16. This transaction was executed in multiple trades at prices ranging from $534.12 to $535.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

17. This transaction was executed in multiple trades at prices ranging from $535.14 to $536.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

18. This transaction was executed in multiple trades at prices ranging from $536.15 to $536.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did United Therapeutics (UTHR) CFO James Edgemond report in this Form 4?

CFO James Edgemond reported exercising options for 10,000 United Therapeutics shares at $135.42 each, then selling 10,000 shares in multiple open-market trades. After these transactions, he directly owns 18,876 common shares, all disclosed for March 23, 2026.

How many United Therapeutics (UTHR) shares does the CFO now hold?

After the reported transactions, CFO James Edgemond directly holds 18,876 shares of United Therapeutics common stock. This figure reflects his position following the 10,000-share option exercise and subsequent 10,000-share open-market sales executed on March 23, 2026.

At what prices did the United Therapeutics (UTHR) CFO sell shares?

The CFO’s 10,000 United Therapeutics shares were sold in multiple trades at reported prices including $518.2830, $529.0430 and $536.2750 per share. Footnotes note numerous executions within specified price ranges, with weighted average prices reported for each transaction group.

Were the United Therapeutics (UTHR) CFO’s trades under a Rule 10b5-1 plan?

Yes. The option exercise and subsequent share sales were conducted under a Rule 10b5-1 trading plan. The footnotes state the plan was entered into on October 31, 2025, indicating these transactions were pre-arranged rather than newly decided at the trade date.

What type of derivative did the United Therapeutics (UTHR) CFO exercise?

He exercised a stock option covering 10,000 shares of United Therapeutics common stock at an exercise price of $135.42 per share. This derivative transaction converted the option into common shares, which were then sold in open-market trades reported in the same Form 4 filing.

Does the Form 4 show net buying or net selling by the United Therapeutics (UTHR) CFO?

The Form 4 shows an option exercise for 10,000 shares and open-market sales totaling 10,000 shares, resulting in a net-sell share balance for the period. Despite the sales, the CFO retains 18,876 United Therapeutics common shares held directly after these transactions.